Back

Amygdala metabolic activity on FDG PET is associated with survival, response to immune checkpoint inhibition, and tumor immune signaling in non-small cell lung cancer

Geist, B. K.; Vraka, C.; Mertel, C. T. S.; Beer, L.; Frille, A.; Herbsthofer, L.; Hermann, N.; Hesse, S.; Kenner, L.; Kifjak, D.; Kluge, K.; Kulterer, O. C.; Lapa, C.; Lieblich, A.; Nakuz, T. S.; Oberndorfer, F.; Kain, R.; Prosch, H.; Sabri, O.; Sattler, B.; Schweiger, T.; Aigner, C.; Spielvogel, C.; Tsomaia, D.; Trachtova, K.; Tomberger, M.; Wirtz, H.; Yu, J.; Grünert, S.; Hacker, M.

2026-09-13 cancer biology
10.64898/2026.09.10.750685 bioRxiv
Show abstract

Amygdala metabolic activity (AmygAc) measured by [18F]FDG PET has been associated with chronic psychological stress and adverse clinical outcomes, but its relationship with antitumor immunity and treatment response remains incompletely understood. We investigated AmygAc as a host-derived imaging biomarker in non-small cell lung cancer (NSCLC) and examined its association with survival, response to immune checkpoint inhibition (ICI), and the tumor immune microenvironment. Methods: In this multicenter retrospective study, baseline [18F]FDG PET scans from 256 treatment-naive patients with NSCLC were analyzed to quantify AmygAc. Overall survival was assessed in the full cohort, and treatment response was evaluated in 79 patients who subsequently received neoadjuvant ICI therapy. AmygAc was integrated with clinical and tumor-derived imaging parameters. To investigate its biological correlates, tumor tissue from a selected subcohort was analyzed using multiplex immunofluorescence and spatial transcriptomics.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.